



Study	P-value		Odds Ratio (95% CrI)
<b>Placebo vs Erlotinib</b>			
direct			1.7e-11 (7.2e-31, 0.084)
indirect	0.009		3.6 (0.053, 6.4e+02)
network			0.24 (0.0075, 3.4)
<b>Lazertinib vs Gefitinib</b>			
direct			2.0e+05 (0.44, 2.0e+21)
indirect	0.00725		1.4e-08 (2.2e-28, 0.79)
network			1.3 (0.0090, 4.7e+02)
<b>Osimertinib vs Lazertinib</b>			
direct			3.5 (0.097, 2.6e+02)
indirect	0.005175		2.4e-14 (3.7e-34, 0.0064)
network			1.1 (0.024, 39.)
<b>Placebo vs Osimertinib</b>			
direct			0.90 (0.050, 10.)
indirect	1e-04		4.9e-18 (1.1e-32, 1.1e-07)
network			0.13 (0.0030, 2.0)